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Abstract: Immune cells (IC) play a crucial role in murine stroke pathophysiology. 
However, data are limited on the role of these cells in ischemic stroke in humans. We 
therefore aimed to characterize and compare peripheral IC subsets in patients with acute 
ischemic stroke/transient ischemic attack (AIS/TIA), chronic cerebrovascular disease 
(CCD) and healthy volunteers (HV). We conducted a case-control study of patients with 
AIS/TIA (n = 116) or CCD (n = 117), and HV (n = 104) who were enrolled at the 
University Hospital Würzburg from 2010 to 2013. We determined the expression and 
quantity of IC subsets in the three study groups and performed correlation analyses with 
demographic and clinical parameters. The quantity of several IC subsets differed between 
the AIS/TIA, CCD, and HV groups. Several clinical and demographic variables independently 
predicted the quantity of IC subsets in patients with AIS/TIA. No significant changes in the 
quantity of IC subsets occurred within the first three days after AIS/TIA. Overall, these 
findings strengthen the evidence for a pathophysiologic role of IC in human ischemic 
stroke and the potential use of IC-based biomarkers for the prediction of stroke risk. A 
comprehensive description of IC kinetics is crucial to enable the design of targeted 
treatment strategies. 
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1. Introduction 
Peripheral immunodepression is a common observation after acute ischemic stroke [1–3] and other 
acute disorders of the central nervous system (CNS), such as cerebral hemorrhage [4] and spinal cord 
injury [5]. This phenomenon was first described more than three decades ago [6]. Since then, numerous 
researchers have tried to delineate the underlying mechanism and its clinical relevance. Today,  
there is consent that lesions of vulnerable areas within the CNS increase sympathetic activity and  
subsequently trigger rapid and extensive apoptosis in lymphatic organs via catecholamines and the  
hypothalamic-pituitary-adrenal axis [7,8]. The adaptive as well as the innate immune systems are involved. 
The stroke-induced immunodeficiency [8] has important clinical implications. It is well known that 
the prognosis of stroke depends on medical complications [9], most of all infections, such as urinary 
tract infections (up to 24% of stroke patients [10]) or pneumonia (up to 22% of patients [10]).  
The latter may be due to an enhanced stroke-related aspiration risk in terms of dysphagia, but 
immunodeficiency may also, in general, increase the vulnerability to post-stroke infections. 
Experimental stroke studies in rodents described the pathophysiologic relevance of immune cell 
subsets [11–16] in the development of acute ischemic stroke (AIS). A protective effect of the total 
absence of lymphocytes [14], lymphopenia [17], or even the temporary depletion of immune cell 
subsets has been demonstrated [13]. The reduction of immune cells in the cerebral microcirculation lowers 
thromboinflammation during the acute phase of stroke, and consecutively results in improved cerebral 
perfusion and protection from stroke [17,18]. As the number of peripheral lymphocytes or their interaction 
with other cells in the cerebral microcirculation can be modulated pharmacologically [17,19,20], targeting 
immune cells in the acute phase after ischemic stroke might become a future treatment option and is of 
high translational relevance. Only recently, two studies analyzing fingolimod in ischemic [21] and 
hemorrhagic stroke [22] were published. Fu and co-workers recently provided an overview of studies 
about immune interventions in acute ischemic stroke in humans [23]. 
While the importance of neuroimmunologic interactions after ischemic stroke—including the role 
of distinct immune cell subsets—is being increasingly recognized [24–29], many questions about the 
regulation of immune cell subsets are still unanswered and have to be clarified before further translation 
of novel preclinical treatment strategies into the clinic. Additionally, despite the crucial role of various 
immune cells in atherosclerotic plaque pathophysiology [30], almost no study has specifically investigated 
the regulation of immune cells in patients with chronic cerebrovascular disease (CCD) [31]. 
This case-control study has been conducted to evaluate whether: (i) peripheral immune cell subsets 
differ between healthy volunteers (HV), patients with acute cerebrovascular disease (AIS/transient 
ischemic attack [TIA]), and those with CCD; and (ii) to identify demographic and clinical predictors of 
the numbers of distinct peripheral immune cells in patients with AIS/TIA. 
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2. Results and Discussion 
2.1. Descriptive Analysis of Patients with Acute Cerebrovascular Disease 
Overall, the study included 116 patients with AIS/TIA. Patients had a mean age of 70 ± 12 years, 
53% were male and 58% of patients presented with an AIS. Baseline clinical severity, measured using 
the National Institutes of Health Stroke Scale (NIHSS) and Barthel Index, was 4.8 ± 6.0 and 74 ± 30, 
respectively. The demographic and clinical characteristics of patients presenting with an AIS or TIA 
are summarized in Table 1. 
Table 1. Baseline characteristics of patients with acute ischemic stroke/transient ischemic attack. 
Characteristic Value (n = 116) 
Age, years 70 ± 12 
Sex, n (%) 
Male 62 (53) 
Female 54 (47) 
Modality, n (%) 
AIS 67 (58) 
TIA 49 (42) 
TOAST criteria, n (%) 
Cardioembolism 70 (60) 
Large-artery atherosclerosis 4 (3) 
Small-vessel occlusion 12 (10) 
Other determined or undetermined etiology 30 (26) 
Thrombolysis, n (%) 34 (29) 
Comorbidities, n (%) 
Hypertension 105 (91) 
Diabetes mellitus 41 (35) 
Hyperlipidemia 80 (69) 
Renal failure 10 (9) 
Atrial fibrillation 37 (32) 
Persistent foramen ovale 28 (24) 
Heart failure 5 (4) 
Coronary artery disease 8 (7) 
Family history of stroke 11 (9) 
Smoking, n (%) 18 (16) 
Pretreatment 
Platelet inhibitor before blood withdrawal, n (%) 87 (75) 
Anticoagulation before blood withdrawal, n (%) 8 (7) 
Lipid-lowering drug before blood withdrawal, n (%) 36 (31) 
Severity of stroke 
National Institutes of Health Stroke Scale at admission 4.8 ± 6.0 
Barthel Index at admission 74 ± 30 
Body mass index, kg/m2 27 ± 5 
HbA1c, mmol/mol 46 ± 13 
  
Int. J. Mol. Sci. 2015, 16 25436 
 
 
Table 1. Cont. 
Characteristic Value (n = 116) 
Lipid profile, mmol/L 
Total cholesterol 202 ± 52 
Low-density lipoprotein 121 ± 45 
High-density lipoprotein 51 ± 15 
Triglycerides 157 ± 153 
Duration between symptom onset and blood withdrawal, h 14 ± 7 
AIS, acute ischemic stroke; HbA1c, glycated hemoglobin; TIA, transient ischemic attack; TOAST, Trial of 
Org 10172 in Acute Stroke Treatment. 
2.2. Comparison of the Number or Fraction of Distinct Immune Cells in Patients with AIS/TIA, CCD, 
and HV 
The numbers or fractions of immune cell subsets in patients with AIS/TIA and CCD and in HV are 
shown in Figure 1 for comparison. For the primary analyses of data (without adjustment for 
confounders, but also adjusted for age and sex), we found significantly higher numbers of leukocytes 
and neutrophils in patients with AIS/TIA (leukocytes, 7.9 ± 2.7/nL; neutrophils, 5.4 ± 2.6/nL) 
compared with patients with CCD (leukocytes, 6.8 ± 1.8/nL, p < 0.001; neutrophils, 4.2 ± 1.4/nL,  
p < 0.001) and HV (leukocytes, 6.5 ± 2.2/nL, p < 0.001; neutrophils, 3.8 ± 1.9/nL, p < 0.001).  
In contrast, lymphocytes were higher in HV (2.0 ± 0.6/nL) compared with patients with CCD  
1.8 ± 0.6/nL, p < 0.05) and those with AIS/TIA (1.6 ± 0.6/nL, p < 0.001). Also FoxP3+ regulatory T 
cells (Treg), a subset of lymphocytes, were decreased in patients with AIS/TIA (2.4% ± 1.2%) 
compared with patients with CCD (3.1% ± 1.2%, p < 0.001) and HV (2.8% ± 1.0%, p < 0.05). There 
was no difference in the number of monocytes as well as the fraction of CD4+CD8− or CD8+CD4− T 
cells between the groups. 
 
Figure 1. Cont. 
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Figure 1. Numbers or fractions of important immune cell subsets in acute ischemic stroke 
(AIS)/transitory ischemic attack (TIA), chronic cerebrovascular disease (CCD), and 
healthy volunteers (HV). The number of leukocytes, neutrophils, lymphocytes, monocytes, 
CD4+CD8−, CD8+CD4−, and FoxP3 regulatory T cells (Treg) are depicted in box-and-whisker 
plots indicating the first and third quartiles as well as the 1.5 interquartile range (IQR, Tukey 
plot). Outliers that lie outside the 1.5 IQR are represented by single dots. The numbers of 
leukocytes, neutrophils, lymphocytes and FoxP3+ Treg differed significantly between the three 
groups, as determined by analysis of variance with Bonferroni post hoc test, *** p < 0.001,  
* p < 0.05. 
2.3. Relationship between the Number or Fraction of Immune Cell Subsets and Key Demographic and 
Clinical Parameters in Patients with Acute Cerebrovascular Disease 
Results from univariate analysis of the association between the number or fraction of immune cells 
subsets and key demographic and clinical characteristics are summarized in Tables 2 and 3. Leukocyte 
(p < 0.001) and neutrophil numbers (p < 0.001) as well as the fraction of FoxP3+ Treg (p = 0.02) were 
higher in patients with AIS compared with patients with TIA. In contrast, the number of monocytes 
was lower in patients with AIS than in patients with TIA (p = 0.02). Older patients showed a lower 
quantity of lymphocytes (p = 0.02) and a smaller fraction of CD4+CD8− T cells (p = 0.03). Severity of 
stroke at admission was associated with different immune cell subsets (NIHSS: leukocytes, p = 0.05, 
neutrophils, p = 0.007, CD4+CD8− cells, p = 0.004; Barthel Index: leukocytes, p = 0.01, neutrophils,  
p = 0.001). Again, leukocytes (p = 0.01) and neutrophils (p = 0.003) were associated with 
thrombolysis. Interestingly, sex and pretreatment with platelet inhibitors did not influence the number 
or fraction of immune cell subsets. 
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Table 2. Predictors of the absolute number or fraction of immune cells in patients with acute ischemic stroke/transient ischemic attack 
(univariate analysis; leukocytes, lymphocytes, neutrophils, monocytes). 
Immune Cell Subset 
Leukocytes/nL  
(Mean ± SD) 
p Value 
Lymphocytes/nL  
(Mean ± SD) 
p Value 
Neutrophils/nL 
(Mean ± SD) 
p Value 
Monocytes/nL 
(Mean ± SD) 
p Value 
Sex 
Male 7.9 ± 2.7 - 1.7 ± 0.5 - 5.4 ± 2.5 - 0.7 ± 0.3 - 
Female 7.9 ± 2.6 0.76 1.6 ± 0.7 0.24 5.5 ± 2.7 0.60 0.6 ± 0.2 0.80 
Age, years 
<55 8.0 ± 3.2 - 2.0 ± 0.6 - 5.1 ± 3.1 - 0.6 ± 0.4 - 
55–64 8.0 ± 2.2 - 1.7 ± 0.5 - 5.5 ± 1.9 - 0.6 ± 0.2 - 
65–74 7.6 ± 2.2 - 1.7 ± 0.7 - 5.2 ± 1.9 - 0.7 ± 0.3 - 
75–84 7.5 ± 2.3 - 1.5 ± 0.5 - 5.3 ± 2.3 - 0.6 ± 0.2 - 
>84 9.0 ± 4.5 0.85 1.3 ± 0.6 0.02 6.9 ± 4.7 0.63 0.6 ± 0.2 0.71 
Disease modality 
AIS 8.6 ± 2.9 - 1.7 ± 0.6 - 6.2 ± 2.8 - 0.6 ± 0.2 - 
TIA 6.9 ± 1.9 <0.001  1.6 ± 0.6 0.36 4.4 ± 1.8 <0.001 0.7 ± 0.3 0.02 
Modified TOAST criteria 
Cardioembolism 8.0 ± 2.9 - 1.6 ± 0.6 - 5.6 ± 2.9 - 0.6 ± 0.2 - 
Large-artery atherosclerosis 7.1 ± 2.0 - 1.8 ± 0.4 - 4.6 ± 1.9 - 0.6 ± 0.1 - 
Small-vessel occlusion 7.8 ± 2.1 - 1.8 ± 0.5 - 5.0 ± 1.9 - 0.7 ± 0.2 - 
Other determined or undetermined etiology 7.7 ± 2.3 0.94 1.5 ± 0.6 0.32 5.4 ± 2.2 0.91 0.6 ± 0.2 0.80 
Duration between symptom onset and blood withdrawal, h 
<5 7.7 ± 2.2 - 1.6 ± 0.6 - 5.4 ± 2.2 - 0.6 ± 0.2 - 
5–12 7.5 ± 2.4 - 1.7 ± 0.6 - 5.0 ± 2.2 - 0.6 ± 0.2 - 
12–24 8.4 ± 2.3 0.14 1.3 ± 0.4 0.63 6.3 ± 2.5 0.05 0.7 ± 0.1 0.80 
National Institutes of Health Stroke Scale 
0–4 7.4 ± 2.2 - 1.7 ± 0.6 - 4.8 ± 2.0 - 0.6 ± 0.2 - 
5–9 8.5 ± 2.8 - 1.5 ± 0.4 - 6.2 ± 2.6 - 0.7 ± 0.3 - 
10–15 8.8 ± 3.1 - 1.7 ± 0.7 - 6.3 ± 2.9 - 0.7 ± 0.3 - 
>15 9.6 ± 4.1 0.05 1.2 ± 0.4 0.06 7.7 ± 4.4 0.007 0.6 ± 0.1 0.88 
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Table 2. Cont. 
Immune Cell Subset 
Leukocytes/nL  
(Mean ± SD) 
p Value 
Lymphocytes/nL  
(Mean ± SD) 
p Value 
Neutrophils/nL 
(Mean ± SD) 
p Value 
Monocytes/nL  
(Mean ± SD) 
p Value 
Barthel Index 
0–30 9.7 ± 4.4 - 1.2 ± 0.6 - 7.7 ± 4.7 - 0.6 ± 0.2 - 
35–70 8.5 ± 2.7 - 1.6 ± 0.5 - 6.1 ± 2.6 - 0.7 ± 0.3 - 
>70 6.9 ± 1.7 0.01 1.8 ± 0.6 0.048 4.3 ± 1.5 0.001 0.6 ± 0.2 0.13 
Thrombolysis 
Yes 8.6 ± 2.2 - 1.6 ± 0.4 - 6.2 ± 2.3 - 0.7 ± 0.3 - 
No 7.6 ± 2.8 0.01 1.7 ± 0.7 0.99 5.1 ± 2.7 0.003 0.6 ± 0.2 0.38 
Platelet inhibitor before blood withdrawal 
Yes 8.0 ± 2.9 - 1.7 ± 0.6  - 5.6 ± 2.9 - 0.6 ± 0.2 - 
No 7.6 ± 2.2 0.60 1.6 ± 0.6 0.42 5.2 ± 2.0 0.83 0.7 ± 0.3 0.81 
AIS, acute ischemic stroke; TIA, transient ischemic stroke; TOAST, Trial of Org 10172 in Acute Stroke Treatment. 
Table 3. Predictors of the absolute number or fraction of immune cells in patients with acute ischemic stroke/transient ischemic attack 
(univariate analysis; (CD4+CD8− T cells, CD8+CD4− T cells, FoxP3 Treg). 
Immune Cell Subset 
CD4+CD8− Cells/Gated 
Cells (%) (Mean ± SD) 
p Value 
CD8+CD4− Cells/Gated 
Cells (%) (Mean ± SD) 
p Value 
FoxP3+ Cells/Gated 
Cells (%) (Mean ± SD) 
p Value 
Sex 
Male 46.3 ± 11.3 - 29.9 ± 11.6 - 2.4 ± 1.1 - 
Female 47.7 ± 11.8 0.51 25.8 ± 9.8 0.04 2.4 ± 1.4 0.36 
Age, years 
<55 50.1 ± 9.8 - 24.9 ± 9.7 - 2.8 ± 1.3 - 
55–64 49.2 ± 11.2 - 28.5 ± 12.2 - 2.3 ± 1.2 - 
65–74 50.1 ± 10.1 - 26.7 ± 9.9 - 2.4 ± 1.2 - 
75–84 41.6 ± 11.8 - 31.8 ± 11.0 - 2.4 ± 1.3 - 
>84 42.5 ± 12.9 0.03 24.9 ± 11.7 0.22 2.2 ± 1.1 0.81 
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Table 3. Cont. 
Immune Cell Subset 
CD4+CD8− Cells/Gated 
Cells (%) (Mean ± SD) 
p Value 
CD8+CD4− Cells/Gated 
Cells (%) (Mean ± SD) 
p Value 
FoxP3+ Cells/Gated 
Cells (%) (Mean ± SD) 
p Value 
Disease modality 
AIS 49.2 ± 10.4 - 26.0 ± 9.6 - 2.7 ± 1.2 - 
TIA 45.3 ± 12.1 0.09 29.4 ± 11.7 0.24 2.2 ± 1.2 0.02 
Modified TOAST criteria 
Cardioembolism 46.0 ± 12.1 - 29.3 ± 11.0 - 2.4 ± 1.3 - 
Large-artery atherosclerosis 55.0 ± 12.2 - 21.2 ± 6.7 - 3.3 ± 1.3 - 
Small-vessel occlusion 51.1 ± 7.2 - 24.8 ± 8.7 - 2.7 ± 1.2 - 
Other determined or undetermined etiology 46.4 ± 11.2 0.27 27.0 ± 12.0 0.35 2.1 ± 1.0 0.23 
Duration between symptom onset and blood withdrawal, h 
<5 49.4 ± 8.5 - 26.4 ± 8.7 - 2.4 ± 1.0 - 
5–12 47.2 ± 11.4 - 27.7 ± 10.1 - 2.5 ± 1.3 - 
12–24 49.8 ± 13.8 0.86 18.9 ± 2.1 0.47 2.7 ± 0.2 0.59 
National Institutes of Health Stroke Scale 
0–4 48.5 ± 10.6 - 26.6 ± 9.5 - 2.5 ± 1.1 - 
5–9 48.7 ± 10.6 - 28.6 ± 10.4 - 2.7 ± 1.4 - 
10–15 47.5 ± 11.2 - 29.1 ± 7.1 - 2.3 ± 1.3 - 
>15 32.2 ± 11.7 0.004 35.2 ± 20.1 0.66 1.4 ± 0.9 0.03 
Barthel Index 
0–30 43.7 ± 12.0 - 23.8 ± 5.2 - 2.0 ± 1.3 - 
35–70 45.6 ± 10.0 - 28.0 ± 11.3 - 2.4 ± 1.2 - 
>70 50.3 ± 9.3 0.16 25.7 ± 8.4 0.58 2.7 ± 1.3 0.37 
Thrombolysis 
Yes 45.4 ± 10.5 - 27.7 ± 13.3 - 2.3 ± 1.4 - 
No 47.6 ± 11.9 0.32 28.1 ± 10.0 0.39 2.4 ± 1.1 0.31 
Platelet inhibitor before blood withdrawal 
Yes 45.6 ± 11.5 - 28.4 ± 10.8 - 2.4 ± 1.2 - 
No 49.3 ± 11.2 0.11 27.3 ± 11.5 0.49 2.4 ± 1.2 0.97 
AIS, acute ischemic stroke; TIA, transient ischemic stroke; TOAST, Trial of Org 10172 in Acute Stroke Treatment. 
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Multivariate analysis (adjusted for age and sex) (Tables 4–7) identified disease modality (AIS vs. 
TIA) as an independent predictor of leukocyte (p = 0.006), neutrophil (p = 0.005), and monocyte count 
(p = 0.04). Sex was only associated with the fraction of CD8+CD4− T cells (p = 0.03). Age only 
accounted for CD4+CD8− T cell regulation (p = 0.012). NIHSS scores were independent predictors of 
the CD4+CD8− as well as the CD8+CD4− fractions (p = 0.02 and 0.03, respectively). We found no 
independent predictor of FoxP3 Treg. In addition, none of the measured variables (leukocytes, p = 0.48; 
neutrophils, p = 0.54; lymphocytes, p = 0.81; monocytes, p = 0.81; CD4+CD8− T cells, p = 0.65; 
CD8+CD4− T cells, p = 0.65; FoxP3 Treg, p = 0.95) were influenced by the time of blood withdrawal 
(Days 0, 1, and 3; data not shown). 
Table 4. Predictors of absolute numbers of leukocytes and lymphocytes in patients with 
acute ischemic stroke/transient ischemic attack (multivariate analysis). 
Immune Cell Subset 
Leukocytes Lymphocytes 
Coefficient 95% CI p Value Coefficient 95% CI p Value 
Sex 
Male Reference - - Reference - - 
Female −0.4 ± 0.9 −1.1 to 1.0 0.93 0.0 ± 0.1 −0.2 to 0.3 0.71 
Age, years - - 0.74 - - 0.003 
<55 Reference - - Reference - - 
55–64 −0.5 ± 0.9 −2.2 to 1.3 - −0.3 ± 0.2 −0.7 to 0.1 - 
65–74 −0.4 ± 0.8 −2.0 to 1.3 - −0.4 ± 0.2 −0.7 to 0.0 - 
75–84 −0.7 ± 0.9 −2.4 to 1.0 - −0.5 ± 0.2 −0.9 to −0.1 - 
>84 0.5 ± 1.1 −1.7 to 2.6 - −0.6 ± 0.2 −1.1 to −0.2 - 
Disease modality (TIA vs. AIS) 1.5 ± 0.5 0.4 to 2.6 0.006 −0.1 ± 0.1 −0.3 to 0.2 0.66 
National Institutes of Health 
Stroke Scale 
- - 0.11 - - 0.052 
0–4 Reference - - Reference - - 
5–9 0.8 ± 0.8 −0.7 to 2.3 - −0.3 ± 0.2 −0.6 to 0.1 - 
10–15 0.8 ± 0.9 −0.9 to 2.6 - −0.1 ± 0.2 −0.5 to 0.3 - 
>15 1.3 ± 1.0 −0.8 to 3.3 - −0.5 ± 0.2 −1.0 to −0.1 - 
Thrombolysis 0.1 ± 0.7 −1.3 to 1.4 0.94 0.1 ± 0.2 −0.20 to 0.4 0.53 
Use of platelet inhibitor before 
blood taking 
0.5 ± 0.5 −0.6 to 1.6 0.34 0.2 ± 0.1 −0.1 to 0.4 0.17 
AIS, acute ischemic stroke; CI, confidence interval; TIA, transient ischemic stroke. 
Table 5. Predictors of absolute numbers of neutrophils and monocytes in patients with 
acute ischemic stroke/transient ischemic attack (multivariate analysis). 
Immune Cell Subset 
Neutrophils Monocytes 
Coefficient 95% CI p Value Coefficient 95% CI p Value 
Sex 
Male Reference - - Reference - - 
Female −0.0 ± 0.5 −1.0 to 0.9 0.98 −0.0 ± 0.1 −0.1 to 0.1 0.53 
Age, years - - 0.25 - - 0.53 
<55 Reference - - Reference - - 
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Table 5. Cont. 
Immune Cell Subset 
Neutrophils Monocytes 
Coefficient 95% CI p Value Coefficient 95% CI p Value 
55–64 −0.1 ± 0.8 −1.8 to 1.5 - −0.0 ± 0.1 −0.2 to 0.1 - 
65–74 0.1 ± 0.8 −1.5 to 1.6 - 0.0 ± 0.1 −0.1 to 0.2 - 
75–84 −0.1 ± 0.8 −1.7 to 1.5 - −0.0 ± 0.1 −0.2 to 0.1 - 
>84 1.2 ± 1.0 −0.8 to 3.2 - −0.1 ± 0.1 −0.3 to 0.1 - 
Disease modality (TIA vs. AIS) 1.5 ± 0.5 0.5 to 2.5 0.005 0.1 ± 0.1 0.0 to 0.2 0.04 
National Institutes of Health Stroke Scale - - 0.031 - - 0.72 
0–4 Reference - - Reference - - 
5–9 1.0 ± 0.7 −0.4 to 2.5 - 0.0 ± 0.1 −0.1 to 0.2 - 
10–15 1.0 ± 0.8 −0.7 to 2.6 - 0.0 ± 0.1 −0.1 to 0.2 - 
>15 1.8 ± 1.0 −0.2 to 3.7 - 0.0 ± 0.1 −0.2 to 0.2 - 
Thrombolysis 0.0 ± 0.6 −1.2 to 1.3 0.96 −0.0 ± 0.1 −0.1 to 0.1 0.88 
Use of platelet inhibitor before blood taking 2.4 ± 1.2 0.1 to 4.7 0.46 −0.0 ± 0.1 −0.1 to 0.1 0.58 
AIS, acute ischemic stroke; CI, confidence interval; TIA, transient ischemic stroke. 
Table 6. Predictors of fractions of CD4+CD8− and CD8+CD4− T cells in patients with acute 
ischemic stroke/transient ischemic attack (multivariate analysis). 
Immune Cell Subset 
CD4+CD8− Cells CD8+CD4− Cells 
Coefficient 95% CI p Value Coefficient 95% CI p Value 
Sex 
Male Reference - - Reference - - 
Female 2.8 ± 2.1 −1.3 to 6.9 0.18 −4.7 ± 2.1 −8.8 to −0.5 0.03 
Age, years - - 0.012 - - 0.63 
<55 Reference - - Reference - - 
55–64 −0.5 ± 3.6 −7.7 to 6.7 - 3.8 ± 3.6 −3.4 to 11.0 - 
65–74 −1.5 ± 3.4 −8.2 to 5.3 - 3.4 ± 3.4 −3.4 to 10.2 - 
75–84 −8.7 ± 3.5 −15.7 to −1.6 - 6.9 ± 3.6 −0.2 to 14.0 - 
>84 −5.0 ± 4.4 −13.7 to 3.7 - −0.6 ± 4.4 −9.3 to 8.2 - 
Disease modality (TIA vs. AIS) −2.7 ± 2.2 −7.1 to 1.7 0.22 2.5 ± 2.2 −1.9 to 6.9 0.26 
National Institutes of Health Stroke Scale - - 0.02 - - 0.03 
0–4 Reference - - Reference - - 
5–9 1.5 ± 3.1 −4.6 to 7.6 - 3.3 ± 3.1 −2.9 to 9.4 - 
10–15 −0.0 ± 3.8 −7.5 to 7.5 - 2.1 ± 3.8 −5.5 to 9.7 - 
>15 −12.9 ± 4.2 −21.2 to −4.7 - 11.2 ± 4.2 2.8 to 19.5 - 
Thrombolysis −1.1 ± 2.7 −6.4 to 4.2 0.67 −0.3 ± 2.7 −8.6 to 2.1 0.24 
Use of platelet inhibitor before blood taking −1.9 ± 2.2 −6.3 to 2.4 0.39 −0.7 ± 2.2 −5.1 to 3.7 0.77 
AIS, acute ischemic stroke; CI, confidence interval; TIA, transient ischemic stroke. 
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Table 7. Predictors of fraction of FoxP3 Treg in patients with acute ischemic 
stroke/transient ischemic attack (multivariate analysis). 
Immune Cell Subset 
FoxP3+ Cells 
Coefficient 95% CI p Value 
Sex 
Male Reference - - 
Female −0.0 ± 0.2 −0.5 to 0.5 0.95 
Age, years - - 0.57 
<55 Reference - - 
55–64 −0.3 ± 0.4 −1.1 to 0.5 - 
65–74 −0.4 ± 0.4 −1.2 to 0.4 - 
75–84 −0.3 ± 0.4 −1.2 to 0.5 - 
>84 −0.2 ± 0.5 −1.2 to 0.8 - 
Disease modality (TIA vs. AIS) −0.4 ± 0.3 −0.9 to 0.2 0.16 
National Institutes of Health Stroke Scale - - 0.13 
0–4 Reference - - 
5–9 0.3 ± 0.4 −0.4 to 0.1 - 
10–15 −0.1 ± 0.4 −0.9 to 0.8 - 
>15 −1.0 ± 0.5 −2.0 to −0.1 - 
Thrombolysis 0.1 ± 0.3 −0.5 to 0.7 0.80 
Use of platelet inhibitor before blood taking 0.1 ± 0.3 −0.4 to 0.6 0.69 
AIS, acute ischemic stroke; CI, confidence interval; TIA, transient ischemic stroke; FoxP3 Treg, regulatory T cells. 
2.4. Discussion 
In this case-control study, we analyzed peripheral immune responses in different cerebrovascular 
disease settings and showed that the number or fraction of distinct immune cell subsets is differentially 
regulated between patients with AIS/TIA and CCD, compared with HV. Moreover, within the 
AIS/TIA group, several clinical (e.g., NIHSS, Barthel index, thrombolysis or not, AIS or TIA) or 
demographic (age, sex) parameters predicted the number or fraction of immune cells even after 
adjustment for age and sex. 
Most of our findings in patients with AIS/TIA are consistent with the results of previously published 
studies regarding ischemic stroke [1,2,32–35]. However, in contrast to other observations [24,36], we 
found no change in the number of monocytes during the observation period until day 3. Of note, a low 
fraction of CD4+CD8− T cells and a high percentage of CD8+CD4− T cells were independently 
associated with high clinical severity of patients with AIS/TIA at admission. This observation can be 
confirmed by a study showing that subjects with a high fraction of CD8+ cells often have comorbidities 
that include insulin resistance and an increased risk of cardiovascular events [36]. Therefore, despite 
evidence for reduced cytotoxic function of CD8+ T cells in AIS [26], it can be hypothesized that 
especially CD8+ cells have detrimental properties in cardiovascular disease. FoxP3 Treg were 
associated with clinical severity in univariate analysis but not after adjustment for age and sex. 
Very importantly, other diseases of the CNS—such as like aneurysmal subarachnoid hemorrhage [4] 
or acute cerebral hemorrhage [25]—are also associated with changes in peripheral immune cell 
homeostasis and distribution, showing that peripheral immune cell modulation is an unspecific 
response to various acute CNS diseases [7,8]. Nevertheless, kinetics of immune cell regulation might 
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be different between various CNS diseases. In contrast to our results in ischemic stroke, Shi et al. [25] 
reported an increase in Treg over time in patients with intracerebral hemorrhage and Sarrafzadeh et al. [4] 
found an increase in CD4+ and CD8+ T cells in a subpopulation of patients in the first days after 
aneurysmal subarachnoid hemorrhage. 
Despite clear evidence that inflammatory mechanisms and immune cells play an important part in 
the pathophysiology of atherosclerosis—including plaque progression and instability [31,37]—to the 
best of our knowledge, this report is the first description of the detailed regulation of immune cell 
subsets in CCD. The numbers of leukocytes, neutrophils, and lymphocytes in patients with CCD lie 
between those seen for patients with AIS/TIA and HV, pointing towards a hypothetical sequence of 
disease from healthy persons to chronic cerebrovascular atherosclerotic lesions (extracranial and/or 
intracranial) and finally AIS. Very interestingly, FoxP3+ Treg were even higher in patients with CCD 
compared with those with AIS/TIA, suggesting a pathophysiologic role of Treg in CCD. Atherosclerosis 
is currently understood as a systemic disease that might also be influenced by pro- and anti-inflammatory 
cytokines. A recent report suggested that the level of detrimental cytokines could be decreased by 
physical exercise [38]. Further studies are needed to better understand the underlying pathophysiology. 
As immune cells are not only biomarkers after ischemic stroke, but also potential therapeutic  
targets [23], a detailed characterization of their regulation is absolutely necessary for elaborating the 
best treatment strategy and also for improving the translation of promising preclinical agents into the 
clinic. We identified several variables that independently predicted the number or fraction of various 
immune cell subsets (AIS vs. TIA, age, sex, NIHSS). It seems that the number of immune cells 
depends on various non-modifiable clinical and demographic variables, making it difficult to develop 
universal treatment strategies. 
There are several limitations to this study that should be considered. First, it should be remembered 
that the potential for reverse causation as a result of blood withdrawal following a cerebrovascular 
event cannot be disregarded. Accordingly, the current study describes the magnitude and significance 
of associations between immune cell subsets and demographic/clinical parameters without attributing 
causality. Further prospective studies are required to formally elucidate causality. Second, all patients 
were required to provide informed consent before participating in the study. However, this may have 
resulted in patients who have suffered a severe stroke and/or aphasia being underrepresented in this 
study because neurological deficits related to their condition may have prevented them from being 
capable of providing informed consent. Third, it was not possible to completely rule out a non-vascular 
origin for symptoms in 42% of the TIA patient population, meaning that the possibility of the 
aforementioned factors influencing the regulation of immune cell subsets remains. 
3. Experimental Section 
3.1. Data Collection 
Patients with acute cerebrovascular disease (AIS/TIA) and CCD were included in this study, while 
control subjects were HV from the local population. All study participants were required to meet the 
following inclusion criteria: for patients presenting with an AIS (i.e., an acute ischemic lesion on brain 
imaging) and TIA (no acute ischemic lesion on brain imaging), blood samples must have been drawn 
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within 24 hours of symptom onset; in the CCD group, patients must have presented with extracranial 
and/or intracranial stenosis of the large cerebral arteries with (n = 66) or without (n = 51) a history of 
AIS or TIA; and for the control HV subjects, aged ≥50 years with no history of stroke, myocardial 
infarction, or peripheral arterial disease. Patients with AIS, TIA or CCD were excluded from the  
study if they presented with intracerebral hemorrhage, were aged <18 years, had a known plasmatic 
coagulation disorder, or a detailed medical history indicated the presence of platelet dysfunction. 
Study participants were consecutively recruited between September 2010 and January 2013 from 
inpatients diagnosed with TIA or AIS in the Stroke Unit, outpatients presenting with CCD, and the HV 
population who responded to recruitment advertisements in the Neurology Department, University 
Hospital of Würzburg, Germany. The study protocol was approved by the ethics committee of the 
Medical Faculty of the University of Würzburg, Germany (reference number 65/2010) and written 
informed consent was provided by all participants. In total, 337 patients were eligible to participate in 
the study, including 116 patients with AIS or TIA, 117 patients with CCD, and 104 HV. Patient treatment 
and care remained at physician discretion and was not affected by participation in this study. 
An adapted version of the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria [39] was 
applied to patients who presented with acute cerebrovascular disease (AIS or TIA): (1) cardioembolism; 
(2) large-artery atherosclerosis; (3) small-vessel occlusion; or (4) other determined or undetermined 
etiology. On patient admission, the interval between symptom onset and blood withdrawal, platelet 
inhibitor pretreatment, and acute stroke therapy modality (thrombolysis vs. no thrombolysis) were 
recorded, as well as NIHSS [40] and Barthel Index scores [41]. 
3.2. Blood Collection and Measurements 
Blood samples were drawn from an antecubital vein using a 21-gauge butterfly needle between 
08.00 and 12.00 h on Days 0, 1, and 3 in patients with acute cerebrovascular disease. Blood samples 
were only drawn once in patients with CCD and HV. Pre-analytic preparations for blood collection 
were carried out according to specific standard operating procedures and only non-hemolyzed blood 
samples were analyzed. Differential hematology—including the absolute number of leukocytes, 
lymphocytes, neutrophils and monocytes—has been analyzed at the Division of Laboratory Medicine 
of the University Hospital Würzburg. Flow cytometric analysis of the fractions of CD4+CD8−, 
CD8+CD4−, and FoxP3+ Treg was performed using peripheral blood mononuclear cells (PBMCs), with 
density gradient centrifugation used to isolate PBMCs from peripheral blood. Cells were analyzed on  
a BD FACSCalibur flow cytometer (BD Biosciences, Heidelberg, Germany). The following primary 
antibodies were used: FoxP3-APC (Cat. no.: 17-4776-42; eBiosciences, Frankfurt, Germany), CD4− 
FITC (Cat. no.: 347413, BD Biosciences, Heidelberg, Germany), and CD8− PE (Cat. no.: 555635;  
BD Biosciences, Heidelberg, Germany). The respective isotype controls were purchased from  
BD Biosciences. The gating strategy is illustrated in Supplementary Figure S1. 
3.3. Statistical Analysis 
Continuous variables are presented as mean ± standard deviation or median with interquartile range, 
as appropriate. Categorical variables are expressed as percentages. Analysis of variance (ANOVA) and 
chi-square tests were used to investigate the association between the absolute number or fraction of 
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immune cell subsets and demographic and clinical characteristics (age, sex, neurologic scales, disease 
modality (TIA or AIS), TOAST criteria, duration between symptom onset and blood withdrawal, 
NIHSS score, Barthel Index score, treatment modality (intravenous thrombolysis or not), and treatment 
with platelet inhibitors in the days before blood withdrawal) and p values derived, as appropriate. 
Coefficients and corresponding 95% confidence intervals for potential predictors of the numbers of 
distinct immune cells were estimated using a linear regression model that included all variables 
without collinearity in a multivariate model that was adjusted for age and sex. Immune cell subsets 
were compared between the different patient groups (inpatients with AIS/TIA, outpatients with CCD, 
or HV), and distributions analyzed using the Kolmogorov-Smirnov test. It was assumed that the 
immune cell numbers were normally distributed and the groups were compared using ANOVA with a 
Bonferroni post-hoc test. These comparisons were additionally adjusted for age and sex. All reported  
p values are derived from two-sided tests, with a p value <0.05 considered to be statistically 
significant. Analyses were performed using SPSS Version 21 and SAS software version 9.1 (SAS 
Institute Inc., Cary, NC, USA). 
4. Conclusions 
Changes in peripheral immune cell numbers are a well-known signature after ischemic stroke.  
At the same time, immune cell subsets play major roles in the pathophysiology of murine ischemic 
stroke and might also become future targets of novel therapeutic approaches in humans. We provide 
here an overview of the regulation of distinct immune cell subsets after AIS/TIA in comparison with 
CCD and HV. The description of independent predictors of immune cells raises new questions, which 
might be valuable for the understanding of pathophysiologic mechanisms, and could finally help to 
enable focused treatment strategies. 
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